Breaking News, Collaborations & Alliances

Carina Biotech Selects CellVec as its Manufacturing Partner

The partnership aims to advance clinical trials for a treatment designed for patients with advanced colorectal (bowel) cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Singapore-based viral vector CDMO CellVec has been selected as the manufacturer of choice for Australian cell therapy immuno-oncology company Carina Biotech, undertaking the production of GMP-compliant lentivirus constructs for its LGR5 CAR-T.   The partnership is slated to advance clinical trials for a treatment designed for patients with advanced colorectal (bowel) cancer.   CellVec is a certified GMP gene therapy contract development and manufacturing organization that provides an advance...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters